[
  {
    "ts": null,
    "headline": "HIMS Stock Declines Despite Launch of New Specialty in Women's Health",
    "summary": "Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.",
    "url": "https://finnhub.io/api/news?id=32b2687c072031fde0f5bcce46f9c3f3e8ac768f4d7d9f5c57518e3472bd145f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761055560,
      "headline": "HIMS Stock Declines Despite Launch of New Specialty in Women's Health",
      "id": 137180737,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.",
      "url": "https://finnhub.io/api/news?id=32b2687c072031fde0f5bcce46f9c3f3e8ac768f4d7d9f5c57518e3472bd145f"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains ResMed (RMD) Overweight Recommendation",
    "summary": "Morgan Stanley Maintains ResMed (RMD) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=aafd773f696b9a110625b58ac055506ec98b0bc8c54c317dd6dccf66154bb3a3",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761048167,
      "headline": "Morgan Stanley Maintains ResMed (RMD) Overweight Recommendation",
      "id": 137177295,
      "image": "",
      "related": "RMD",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=aafd773f696b9a110625b58ac055506ec98b0bc8c54c317dd6dccf66154bb3a3"
    }
  },
  {
    "ts": null,
    "headline": "Home Healthcare Market Research Report 2025-2030: Leading Companies are Innovating and Introducing New Home Healthcare Products to Gain a Competitive Advantage",
    "summary": "The global home healthcare market is projected to reach USD 473.8 billion by 2030, up from USD 309.9 billion in 2025, growing at a CAGR of 8.9%. This expansion is driven by rising lifestyle-related disorders such as high blood pressure, obesity, and cardiac conditions. Leading companies are innovating and introducing new home healthcare products. The therapeutic products segment holds the largest market share, fueled by a growing prevalence of chronic health conditions. Skilled nursing services",
    "url": "https://finnhub.io/api/news?id=e2844ad66686cf216a6d30da1315b952146cec0e30a6e0510a0dcd8a2b66ebbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761038520,
      "headline": "Home Healthcare Market Research Report 2025-2030: Leading Companies are Innovating and Introducing New Home Healthcare Products to Gain a Competitive Advantage",
      "id": 137174740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "The global home healthcare market is projected to reach USD 473.8 billion by 2030, up from USD 309.9 billion in 2025, growing at a CAGR of 8.9%. This expansion is driven by rising lifestyle-related disorders such as high blood pressure, obesity, and cardiac conditions. Leading companies are innovating and introducing new home healthcare products. The therapeutic products segment holds the largest market share, fueled by a growing prevalence of chronic health conditions. Skilled nursing services",
      "url": "https://finnhub.io/api/news?id=e2844ad66686cf216a6d30da1315b952146cec0e30a6e0510a0dcd8a2b66ebbf"
    }
  },
  {
    "ts": null,
    "headline": "PolyNovo (ASX:PNV): Valuation Perspectives Following Board Appointment of ResMed Veteran Robert Douglas",
    "summary": "PolyNovo (ASX:PNV) has appointed Robert Douglas to its Board of Directors, a move that brings decades of international medical device leadership into the mix. Investors are tuning in to see what his experience could mean for PolyNovo’s strategic direction. See our latest analysis for PolyNovo. PolyNovo’s recent board appointment arrives just as its share price faces volatility, slipping 20% over the past month and down nearly 39% year-to-date. Longer-term shareholders have felt the pressure...",
    "url": "https://finnhub.io/api/news?id=1ba553a207816fa57aa90fa46aff0ac1f7bcb8128fd87bcbe1e3107f5a21d3e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761016152,
      "headline": "PolyNovo (ASX:PNV): Valuation Perspectives Following Board Appointment of ResMed Veteran Robert Douglas",
      "id": 137174741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "PolyNovo (ASX:PNV) has appointed Robert Douglas to its Board of Directors, a move that brings decades of international medical device leadership into the mix. Investors are tuning in to see what his experience could mean for PolyNovo’s strategic direction. See our latest analysis for PolyNovo. PolyNovo’s recent board appointment arrives just as its share price faces volatility, slipping 20% over the past month and down nearly 39% year-to-date. Longer-term shareholders have felt the pressure...",
      "url": "https://finnhub.io/api/news?id=1ba553a207816fa57aa90fa46aff0ac1f7bcb8128fd87bcbe1e3107f5a21d3e6"
    }
  }
]